![]() Blueprint Medicines will explore options to advance and simplify the continued global commercialization and development of Gavreto. The termination will be effective 12 months from the notification date of Feb. Read more Roche Decides To Terminate Cancer Treatment Pact With Blueprint Medicines | T17:17:19.000Zīlueprint Medicines Corporation (NASDAQ: BPMC) will regain global commercialization and development rights to Gavreto (pralsetinib), excluding Greater China, following a decision by Roche Holdings AG (OTC: RHHBY) to discontinue the collaboration agreement for strategic reasons. ![]() New results further highlight the benefits of AYVAKIT on pathological mast cell burden, disease symptoms – including total symptom score (TSS), most severe symptom. ![]() As previously reported, AYVAKIT achieved statistically significant and clinically meaningful improvements on the primary and all key secondary endpoints. Read more Blueprint Medicines Presents Registrational Data from PIONEER Trial of AYVAKIT® (avapritinib) in Patients with Indolent Systemic Mastocytosis at 2023 AAAAI Annual Meeting | T20:00:00.000Zīlueprint Medicines Corporation (NASDAQ: BPMC) today announced detailed results from the PIONEER trial of AYVAKIT® (avapritinib) in patients with indolent systemic mastocytosis (SM). ![]() New results further highlight the benefits of Ayvakit on pathological mast cell burden, disease symptoms – including total symptom score (TSS), most severe sympto. As previously reported, Ayvakit achieved statistically significant and clinically meaningful improvements on the primary and all key secondary endpoints. Blueprint Medicines Highlights Detailed Data From Lead Product In Blood Cancer Patients | T18:01:12.000Zīlueprint Medicines Corporation (NASDAQ: BPMC) announced detailed results from the PIONEER Phase 2 trial of Ayvakit (avapritinib) in patients with indolent systemic mastocytosis (SM). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |